Abvc Biopharma, Inc.

Name: Abvc Biopharma, Inc. standardized financial statements, quarterly
Creator: Listed

ABVCNasdaqCIK 1173313HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue−$499.9k, Q4 FY2025

Operating income−$779.5k, Q2 FY2026

Net income−$736.9k, Q2 FY2026

Abvc Biopharma, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	15.9	2.2	1.2	117	389	2.0	not reported	not reported	796	(500)	not reported	not reported
Cost of revenue	$k	29.6	139	0.3	0.2	0.3	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	(13.7)	(137)	0.9	117	389	2.0	not reported	not reported	796	not reported	not reported	not reported
Research and development	$k	141	72.2	69.1	40.4	37.8	32.0	28.9	33.3	29.9	29.1	33.1	22.7
Selling, general and administrative	$k	1,182	1,527	738	654	558	311	615	690	798	784	752	504
Operating income	$k	(2,155)	(512)	(2,838)	(860)	(302)	(705)	(693)	(2,295)	(1,964)	(2,199)	(1,572)	(780)
Interest expense	$k	1,219	(76.4)	182	207	220	217	223	129	31.0	32.6	49.4	42.3
Income tax	$k	(1.0)	175	not reported	(111)	0.4	0.0	not reported	23.6	0.5	0.0	not reported	not reported
Net income	$k	(3,318)	(383)	(2,834)	(942)	(395)	(732)	(842)	(2,257)	(2,042)	(2,767)	(1,560)	(737)
Diluted EPS	$ per share	(0.82)	not reported	(0.29)	(0.08)	(0.03)	not reported	(0.06)	(0.13)	(0.09)	not reported	(0.06)	(0.03)
Basic EPS	$ per share	(0.82)	not reported	(0.29)	(0.08)	(0.03)	not reported	(0.06)	(0.13)	(0.09)	not reported	(0.06)	(0.03)

Balance sheet

Cash and equivalents$31.9k, Q2 FY2026

Shareholders' equity$10.3m, Q2 FY2026

Abvc Biopharma, Inc., balance sheet, quarterly
Line item	Unit	Q1 FY20242024-03-31	period not labelled2024-04-11	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	period not labelled2025-07-31	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.0	0.0	0.1	0.1	0.2	0.2	0.4	0.1	0.2	0.7	0.1	0.0
Current assets	$m	1.8	not reported	2.3	2.2	2.2	1.5	2.8	not reported	3.3	2.5	0.6	0.4
Total assets	$m	8.0	not reported	8.0	7.8	7.5	14.9	16.2	not reported	21.2	21.1	19.7	19.4
Current liabilities	$m	6.2	not reported	6.2	6.2	6.6	6.7	6.5	not reported	6.5	6.2	5.4	5.7
Total liabilities	$m	6.5	not reported	6.5	6.4	6.8	6.9	6.8	not reported	6.7	7.8	6.9	7.1
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	0.9	not reported	0.8	0.9	0.8	0.8	0.9	not reported	0.8	0.8	0.1	0.1
Shareholders' equity	$m	1.7	not reported	1.8	1.6	1.2	5.4	7.0	not reported	12.1	11.1	10.8	10.3

Cash flow

Operating cash flow−$244.4k, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Abvc Biopharma, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,359)	(430)	(956)	(211)	60.2	(702)	(540)	(894)	(965)	(588)	(894)	(244)
Capital expenditure	$k	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)26.06m, Q2 FY2026

Abvc Biopharma, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	3.3	3.3	3.3	4.1	9.7	11.3	12.4	15.0	17.4	23.3	25.4	26.1

Shares outstanding: 26.65m at Aug 10, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.